Announcements Trials

Browse Landscape

Phase

Phase NA 16 Phase 4 3 Phase 2 2 Phase 1 2 Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2 Other hematologic neoplasm 2 Myeloid 2 Lymphoid 2 Breast 2 Plasma cell 1 NET 1 Genitourinary 1 Gastrointestinal 1 Endocrine 1 Dermatologic 1 CNS 1

Conditions

Skin Neoplasms 1 Melanoma 1

Interventions

pembrolizumab 81 Nivolumab 55 Ipilimumab 44 Cyclophosphamide 37 aldesleukin 26 Interleukin-2 25 Temozolomide 17 fludarabine 16 fludarabine phosphate 15 trametinib 11 dabrafenib 11 Radiotherapy 11 Biopsy 11 avelumab 10 Paclitaxel 9 spartalizumab 8 cemiplimab 8 Dacarbazine 8 Cisplatin 8 Bevacizumab 8 sargramostim 7 binimetinib 7 Fluorouracil 7 poly ICLC 6 lenvatinib 6 epacadostat 6 atezolizumab 6 Magnetic Resonance Spectroscopy 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 montanide ISA 51 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Blood Specimen Collection × Dermatologic × Clear all

NCT07422805 2026-05-27

ctDNA

Institute of Oncology Ljubljana

Phase 1/2 Active not recruiting

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡